From GlobeNewswire:

Nurix Therapeutics, Inc. will present the company’s achievements in 2023 and major goals for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 p.m. PT. The presentation will be accessible via a link in the Investors section of the Nurix website and will be available for 30 days after the event. Nurix Therapeutics focuses on developing targeted protein modulation drugs to treat hematologic malignancies and solid tumors. The company’s current pipeline includes drugs targeting B-cell signaling proteins and inhibitors of enzymes regulating immune cell activation. Nurix Therapeutics is based in San Francisco, California. For more information, visit www.nurixtx.com. For further inquiries, contact the relevant parties at [email protected] or [email protected] or [email protected].



Read more: Nurix Therapeutics to Present at 42nd Annual J.P. Morgan